Gilead Sciences (GILD) Short term Debt (2009 - 2026)

Gilead Sciences has reported Short term Debt for 18 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt fell 53.21% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 53.21% YoY), and the FY2025 full-year result was $2.8 billion, up 54.66% from the prior year.
• Short term Debt for Q1 2026 stood at $1.3 billion, down from $2.8 billion in the prior quarter.
• The five-year high for Short term Debt was $4.0 billion in Q2 2023, with the low at $1.0 billion in Q2 2022.
• Historically, Short term Debt has averaged $2.2 billion across 5 years, with a median of $2.3 billion in 2022.
• Annual changes were most pronounced in 2023 — Short term Debt surged 295.4% — and 2024, when it slumped 55.16%.
• Gilead Sciences' Short term Debt stood at $2.3 billion in 2022, then retreated by 20.9% to $1.8 billion in 2023, then gained by 0.95% to $1.8 billion in 2024, then jumped by 54.66% to $2.8 billion in 2025, then sank by 53.22% to $1.3 billion in 2026.
• The last three Short term Debt figures came in at $1.3 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.8 billion (Q3 2025), per Business Quant data.